Severe COVID-19 in a renal transplant recipient: A focus on pharmacokinetics.
Am J Transplant
; 20(7): 1896-1901, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: covidwho-125541
ABSTRACT
The current coronavirus disease 2019 (COVID-19) pandemic requires extra attention for immunocompromised patients, including solid organ transplant recipients. We report on a case of a 35-year-old renal transplant recipient who suffered from a severe COVID-19 pneumonia. The clinical course was complicated by extreme overexposure to the mammalian target of rapamycin inhibitor everolimus, following coadministration of chloroquine and lopinavir/ritonavir therapy. The case is illustrative for dilemmas that transplant professionals may face in the absence of evidence-based COVID-19 therapy and concurrent pressure for exploration of experimental pharmacological treatment options. However, the risk-benefit balance of experimental or off-label therapy may be weighed differently in organ transplant recipients than in otherwise healthy COVID-19 patients, owing to their immunocompromised status and potential drug interactions with immunosuppressive therapy. With this case report, we aimed to achieve increased awareness and improved management of drug-drug interactions associated with the various treatment options for COVID-19 in renal transplant patients.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Neumonía Viral
/
Trasplante de Riñón
/
Infecciones por Coronavirus
/
Receptores de Trasplantes
/
Everolimus
/
Fallo Renal Crónico
Tipo de estudio:
Reporte de caso
/
Estudio pronóstico
Tópicos:
Covid persistente
Límite:
Adulto
/
Humanos
/
Masculino
País/Región como asunto:
Europa
Idioma:
Inglés
Revista:
Am J Transplant
Asunto de la revista:
Trasplante
Año:
2020
Tipo del documento:
Artículo
País de afiliación:
Ajt.15943
Similares
MEDLINE
...
LILACS
LIS